We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
-28.34%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$92.6M
Cap. Flow
+$142M
Cap. Flow %
54.19%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
BRZE icon
Braze
BRZE
+$170M

Top Sells

Rank Stock Value
1
AI icon
C3.ai
AI
+$27.1M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$1.07M

Sector Composition

Rank Sector Weight
1 Technology 53.76%
2 Healthcare 39.71%
3 Consumer Discretionary 6.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRZE icon
1
Braze
BRZE
$2.65B
$141M 53.76%
+3,394,219
New +$170M
PMVP icon
2
PMV Pharmaceuticals
PMVP
$62.9M
$67.4M 25.73%
3,234,911
– –
GKOS icon
3
Glaukos
GKOS
$8.92B
$20.3M 7.74%
350,264
– –
REAL icon
4
The RealReal
REAL
$1.4B
$17.1M 6.53%
2,354,080
– –
SERA icon
5
Sera Prognostics
SERA
$80.3M
$9.16M 3.5%
2,416,241
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.66M 1.78%
18,700
-6,797
-27% -$1.07M
AGTC
7
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.5M 0.57%
1,404,515
– –
VERO
8
DELISTED
Venus Concept
VERO
$942K 0.36%
3,992
– –
DARE icon
9
Dare Bioscience
DARE
$19.8M
$92K 0.04%
5,172
– –
AI icon
10
C3.ai
AI
$1.37B
– –
-866,774
Closed -$27.1M

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q1 2022 Portfolio in Review

As of Q1 2022, InterWest Venture Management held 10 positions worth $262M, up 55% from $169M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management deployed $142M of net new capital in Q1 2022, opening 1 new position. Its largest new stake was Braze: 3,394,219 shares worth $141M.

By sector, the portfolio is most concentrated in Technology at 54% of assets, up from 16% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Eiger BioPharmaceuticals, Inc., an estimated $1.07M trimmed.

  • InterWest Venture Management's largest Q1 2022 buy was Braze: 3,394,219 shares worth $141M.
  • InterWest Venture Management's biggest Q1 2022 reduction was Eiger BioPharmaceuticals, Inc., cutting an estimated $1.07M.
  • InterWest Venture Management fully exited C3.ai in Q1 2022, selling an estimated $27.1M.
  • InterWest Venture Management's ten largest holdings make up 100% of its $262M portfolio in Q1 2022.
  • InterWest Venture Management opened 1 new position and closed 1 in Q1 2022.
  • InterWest Venture Management's portfolio value rose 55% quarter-over-quarter to $262M.

Based on InterWest Venture Management's 13F filing for Q1 2022, filed 13 Apr 2022.